FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ngton, D.C. 20549	OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Yoder Amy					2. Issuer Name <b>and</b> Ticker or Trading Symbol Arcadia Biosciences, Inc. [ RKDA ]							Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner				
(Last) (First) (Middle) C/O ARCADIA BIOSCIENCES, INC.					3. Date of Earliest Transaction (Month/Day/Year) 08/07/2017							Officer ( below)	give title	Other (s below)	pecify	
202 COUSTEAU PLACE, SUITE 105  (Street)  DAVIS  (City)  (State)  (Zip)				4	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date					2A. Deemed Execution Date if any (Month/Day/Yea		Code (Inst	n Disposed	ties Acquired (A) or d Of (D) (Instr. 3, 4 and 5 (A) or (D) Price		Securities Beneficial Owned Fo Reported Transaction	Beneficially (D) o Owned Following (I) (In		7. Nature of ndirect Beneficial Ownership (Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(s)		
Stock Option (right to buy)	\$0.43	08/07/2017		A		202,447		08/07/2018 <sup>(1)</sup>	08/07/2027	Common Stock	202,447	\$0.00	202,447	D		

## **Explanation of Responses:**

1. The shares subject to the Option shall vest and become exercisable in three (3) equal annual installments, with one-third of the shares subject to the Option vesting on each of the first three (3) anniversaries of the date of the award, subject to Participant's continued service through each applicable vesting date.

## Remarks:

Amy J. Yoder, by Attorney-in-Fact, Sally Feng

08/09/2017

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.